Recent literature has pointed to new trends in the treatment of atrophic rhinitis. Soskin and Bernheimer1 have pointed out that the good results reported with the use of estrogenic substances in the treatment of atrophic rhinitis were due to the secondary hyperemia associated with direct nasal application of estrogens. They expressed the belief that the primary hormonal effects were not the essential factor and used prostigmine methylsulfate successfully to produce a prolonged hyperemia in patients with atrophic rhinitis. Whether the pathologic change of atrophic rhinitis is primary, as the so-called ozena, or secondary in type, resulting from infection, the atrophy is dependent on limitation of the blood supply. The other changes, such as mucoid degeneration of the epithelium with later squamification, periglandular lymphocytic infiltration, glandular proliferation and diminution in volume of tissue, are directly and indirectly related to the local changes in blood volume. In ozena the obliterative endarteritis brings
HENNER R, BUSBY W. PROSTIGMINE THERAPY OF ATROPHIC RHINITIS. Arch Otolaryngol. 1943;38(5):426–432. doi:10.1001/archotol.1943.00670040445002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: